daytrade diaries... october 19, page-119

SLA, thinly traded but high quality biotech, over 3m hours of PHD research has gone in to its products over many years, and in the last few months the company received approval for distribution in SE Asia and are currently in trial phase at Melbourne's St Vincents hospital. Buyers are building and I think this signals the end of its retrace from the last very positive announcement, which as I have already alluded to has fundamentally de-risked this company. The company has signalled a new investment and distribution partner, and the ANN re this is due very soon. We might see some renewed interest in the lead up. IMO its a good entry price at the present, and perhaps one to keep safe in your watchlist for any breakouts on news. Remeber, this shot up 300% last time as its tightly held. All the best.